WhiteHawk Capital Partners, LP ("WhiteHawk"), a private credit investment manager focused on asset-based financing solutions, announced it has entered into an agreement with Nephron Pharmaceuticals, LLC (“Nephron” or the “Company”) to provide a $350 million asset-based credit facility (the "Financing"). Nephron will use proceeds of the Financing to support a recapitalization and liquidity for continued growth.
Nephron, founded in 1997 by Lou and Bill Kennedy, is a leading provider of generic respiratory and 503B outsourcing medications with significant expertise in sterile dose medications and compounded solutions. The Company develops, tests, produces, and ships high volumes of sterile drugs in various formats including vials, bottles, IV bags, and pre-filled syringes. Nephron’s state-of-the-art manufacturing facility and headquarters is located in West Columbia, South Carolina.
“Nephron is pleased to collaborate with WhiteHawk as we embark on an exciting journey of growth and innovation in 2025. Our recapitalization marks a pivotal step in our commitment to setting new standards for excellence in the industry,” said Lou Kennedy, Co-Owner and CEO of Nephron.
“Nephron is on an impressive growth trajectory, solidifying its position as a premier provider of essential pharmaceuticals to wholesalers, retailers, and hospitals across the nation,” said Rob Chimenti, Managing Director at WhiteHawk. “We are proud to partner with a Company that not only delivers life-saving products but also plays a crucial role in addressing drug shortages and ultimately strengthening the resilience of our overall healthcare system.”
About WhiteHawk:
WhiteHawk Capital Partners, LP is a private credit investment manager focused on asset-based financing solutions primarily to middle market private and public companies across a variety of industries. WhiteHawk provides senior secured financings under a variety of structures for purposes of refinancing, recapitalization, growth, acquisition, restructuring, bridge, and DIP/emergence. For more information visit www.whitehawkcapital.com or contact info@whitehawkcapital.com.
About Nephron:
For more information visit www.nephronpharm.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250109720495/en/
